Clinical trial NCT02727699: A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
Official title: XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Dementia, Alzheimer Type
Keywords: Dementia
Alzheimer's Disease
Xanamem
UE2343 (Laboratory Code for Xanamem)
Cortisol
XanADu
Actinogen
11β-HSD1
11-beta-Hydroxysteroid Dehydrogenase Type 1
Mild Alzheimer's Disease
Cognitive Impairments
emestedastat
Lead sponsor: Actinogen Medical
Sponsor class: INDUSTRY
Collaborators: name: ICON Clinical Research
First posted: 2016-04-05
Enrollment: 185
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease. Subjects will be randomized to receive either 10mg once daily Xanamem or Placebo at a 1:1 ratio in a double-blinded fashion.

Detailed description: This is a Phase II, randomised, multi-centre, double-blind, placebo-controlled proof-of-concept study to assess the safety, tolerability and efficacy of oral Xanamem once daily in adult subjects with mild dementia due to AD.

Based on Xanamem's mode of action on hippocampal function, amnestic symptoms may respond best, thus favouring the inclusion of mild dementia due to AD, with given evidence of disease progression. Subjects will be treated in a double-blind fashion, where both the investigators and subjects will be unaware of the treatment assignments, to minimise any subjective or unrecognised bias carried by the investigators and subjects. Placebo will be used as the comparator in this study.

It is planned to randomise approximately 174 subjects at approximately 25 study sites in three countries (Australia, United Kingdom, and United States), with the aim to enrol 7 to 10 subjects at each study site. Subject enrolment will be competitive but a cap of 20 subjects per study site is to be established to avoid any side effects. In case the sample composition at one study site is creating concerns, an enrolment stop can also occur at fewer than 20 subjects.

At study end, a total of 185 subjects were randomised into this study and received active treatment.

The data safety monitoring board (DSMB) will periodically meet for the review of accumulating safety study data and will also be involved in the interim analysis.

At the Baseline visit (Week 0), eligible subjects will be randomised on a 1:1 ratio to receive either Xanamem administered orally once daily (QD) for the treatment group or matching placebo for the placebo group. Subjects will return to the study site for visits at Week 4 and Week 8, End of Treatment (Week 12) and Follow-up (4 weeks post last dose of study drug) visits, at which study assessments will be performed.

Ad hoc telephone contact may also occur at any other time-point throughout the study, if deemed necessary by the investigator/study nurse, or if the subject wishes to report an Adverse Event (AE)

Subjects will be interviewed and examined at the study site at each visit and will complete a variety of questionnaires and routine safety evaluations.

Optional Pharmacodynamic (PD) sampling will be performed at specific visits. Subjects who do not provide consent for this optional sub-study will still be eligible for the main study.

The overall study duration for an individual subject will be 17 to 20 weeks, including a screening period of one to 4 weeks, a double-blind treatment period of 12 weeks, and a follow-up period of 4 weeks. The total duration of the study is expected to be 2 years.

Eligibility criteria: Inclusion Criteria:

1. Males and females aged 50 years or older at the time of informed consent.
2. Female Subjects:

   1. Post menopausal women, defined as no menses for 12 months without an alternative medical cause. If there is any concern about the menopausal status of a prospective female subject, a follicle stimulating hormone test (FSH) should be requested to confirm post-menopausal status. Post menopausal women confirmed by FSH level \> 40 mIU (milli-international units per milliliter) /mL, will be confirmed by central laboratory.
   2. Women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening and Baseline, and be willing to use highly effective methods of contraception from the Screening visit until 3 months after last dose of study drug. If re-test is required, a local urine pregnancy test will be performed at Baseline to determine if the subject can continue to randomisation.
   3. Are permanently sterile or have had a hysterectomy, bilateral salpingectomy or bilateral oophorectomy.
   4. Women must not be breastfeeding.
3. Male Subjects:

   1. Who are sexually active, fertile men must use highly effective methods of contraception from Day 1 until 3 months after last dose of study drug if their partners are WOCBP.
   2. Who are permanently sterile or have had bilateral orchiectomy.
4. Diagnosis of mild dementia due to Alzheimer's disease (AD) with increased level of certainty (provided by evidence of clinical deterioration within the 6 months preceding Screening, as assessed by the investigator) as determined by the National Institute of Ageing (NIA) and the Alzheimer's Association (AA) workgroup.
5. Mild dementia due to probable AD with Mini-Mental Status Examination (MMSE) 20 to 26 (inclusive).
6. Clinical Dementia Rating Scale (CDR) Global Score of 0.5 to 1.0.
7. A brain magnetic resonance imaging (MRI) or computed tomography (CT) scan in the 12 months preceding Screening that in the investigator's opinion is consistent with AD as the principle aetiology of the dementia with no other clinically significant abnormality, e.g. another principle underlying aetiology of the subject's dementia, or a lesion which could affect cognition e.g. a brain tumour or large stroke.
8. On stable dose of acetylcholinesterase (AChEI) and/or memantine (at least 3 months prior to Screening) OR treatment-naïve. Initiating AChEIs or memantine during the study will not be permitted.
9. Apart from a clinical diagnosis of mild dementia due to AD, the subject must be in good health as determined by the investigator, based on medical history and screening assessments.
10. Has a consenting study partner who, in the investigator's judgement, has frequent and sufficient contact with the subject to be able to provide accurate information as to the subject's cognitive and functional abilities. The study partner must be available to provide information to the investigator and study site staff about the subject and agrees to attend all study site visits in person for scale completion. A study partner should be available for the duration of the study. The measure of adequate availability will be at the investigator's discretion.
11. Must be willing and able to comply with the requirements of the protocol and must be available to complete the study.
12. Must satisfy a medical examiner about their fitness to participate in the study.
13. Must provide written informed consent to participate in the study.

Exclusion Criteria:

1. Clinically significant abnormalities in vital signs (blood pressure, heart rate, respiration rate and oral temperature), as determined by the investigator.
2. Clinically significant abnormal haematology, biochemistry and urine examination values, specifically abnormal liver and renal function and Vitamin B12 levels below lower threshold since these parameters may impact cognitive function, as determined by the investigator.
3. Has had a significant systematic illness or infection within the past 4 weeks prior to randomisation, as determined by the investigator.
4. Clinically significant neurological disease other than AD, such as (but not limited to) Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumour, progressive supranuclear palsy, seizure disorder, subdural haematoma, multiple sclerosis or a history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
5. Subjects with clinical evidence of peripheral neuropathy or historical evidence of clinically significant nerve conduction abnormalities.
6. Has had a stroke within the year prior to randomisation, as determined by the investigator.
7. Has a lifetime diagnosis of a major psychiatric disorder (other than dementia), based on the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition criteria. This includes but is not limited to schizophrenia, schizoaffective disorder, bipolar affective disorder, alcohol dependence syndrome or major depressive disorder.
8. Has a history of disease directly related to the hypothalamus, the pituitary and/or the adrenal glands which affect the hypothalamic-pituitary-adrenal axis function.
9. Has uncontrolled clinical conditions relating to glucose and lipid metabolism.
10. Clinically significant electrocardiogram (ECG) abnormalities, including Corrected QT interval (QTc) \> 450 ms, following ECG tracings at Screening.
11. Use of any prohibited medication as detailed in the study protocol.
12. Participation in another clinical study of an investigational drug or device whereby the last investigational drug/device administration is within 60 days of Screening.
13. Inability to communicate well with the investigator (i.e. language problem, non-fluent English \[as scales will be provided in English only\], poor mental development or impaired cerebral function).
14. Subject will undergo the tests, Alzheimer's Disease Assessment Scales (ADAS)-Cog v14, CDR-Sum of Boxes (SOB), MMSE, Neuropsychological Test Battery (NTB; executive domain) and RAVLT at the indicated time-points to avoid uncontrolled learning effects. Subjects who need to perform these tests externally to and in parallel with this study will be excluded.
15. Subject has ingested any food or drink containing grapefruit, Seville oranges, star fruit or derived products (e.g. fruit juice), for at least 3 days prior to the first administration of study drug.

Primary outcomes:
measure: ADAS-Cog v14
timeFrame: Baseline, Week 12
measure: AD COMposite Scores
timeFrame: Baseline, Week 12
Secondary outcomes:
measure: RAVLT
timeFrame: Baseline, Week 12
measure: CDR-SOB
timeFrame: Baseline, Week 12
measure: MMSE
timeFrame: Baseline, Week 12
measure: NPI (Neuropsychiatric Inventory)
timeFrame: Baseline, Week 12
measure: NTB - Executive Domain
timeFrame: Baseline, Week 12
Other outcomes:
measure: Pregnancy Test
timeFrame: Screening, baseline, Week 4, Week, 8, Week 12, Week 16
measure: Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Testosterone
timeFrame: Screening, baseline, Week 4, Week, 8, Week 12, Week 16
measure: Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Androstenedione
timeFrame: Screening, baseline, Week 4, Week, 8, Week 12, Week 16
measure: Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Dehydroepiandrosterone Sulfate (DHEAS)
timeFrame: Screening, baseline, Week 4, Week, 8, Week 12, Week 16
measure: Optional PD Assessment - Changes in Pharmacodynamic (PD) Measures of Adrenocorticotropic Hormone (ACTH)
timeFrame: Screening, baseline, Week 4, Week, 8, Week 12, Week 16
measure: Change in Pharmacokinetics (PK), Including Analysis of Cortisol Levels
timeFrame: Baseline, Week 4, Week 8, Week 12 and Unscheduled Safety Visit
measure: NTSS-6
timeFrame: Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc and Unscheduled Safety Visit
measure: NFM
timeFrame: Screening, Baseline, Week 4, Week 8, Week 12, Week 16
measure: Vital Signs
timeFrame: Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Unscheduled Safety Visit
measure: Metabolic Function
timeFrame: Baseline, Week 12
measure: Clinical Safety Laboratory Values
timeFrame: Screening, Baseline, Week 4, Week 8, Week 12, Week 16
measure: AEs
timeFrame: Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Ad Hoc
measure: ECG
timeFrame: Screening, Baseline, Week 4, Week 8, Week 12, Week 16
measure: CSSRS
timeFrame: Screening, Week 4, Week 8, Week 12, Week 16
Locations:
city: Tucson
country: United States
facility: Tucson Neuroscience Research, LLC
state: Arizona
city: Los Angeles
country: United States
facility: National Research Institute
state: California
city: Poway
country: United States
facility: PCND Neuroscience Research Institute
state: California
city: San Diego
country: United States
facility: Pacific Research Network, Inc.
state: California
city: Clearwater
country: United States
facility: Research Alliance Inc.
state: Florida
city: Miami
country: United States
facility: The Neurology Research Group, LLC
state: Florida
city: Orlando
country: United States
facility: Compass Research LLC
state: Florida
city: Palmetto Bay
country: United States
facility: IMIC, Inc.
state: Florida
city: Atlanta
country: United States
facility: Atlanta Center for Medical Research
state: Georgia
city: Decatur
country: United States
facility: NeuroStudies.Net, LLC
state: Georgia
city: Mount Arlington
country: United States
facility: The NeuroCognitive Institute
state: New Jersey
city: Staten Island
country: United States
facility: Richmond Behavioral Associates
state: New York
city: Rocky Mount
country: United States
facility: PMG Research of Rocky Mount, LLC
state: North Carolina
city: Jenkintown
country: United States
facility: The Clinical Trial Center
state: Pennsylvania
city: Central Coast
country: Australia
facility: Central Coast Neurosciences Research
state: New South Wales
city: Darlinghurst
country: Australia
facility: St Vincent's Hospital Sydney
state: New South Wales
city: Macquarie Park
country: Australia
facility: KaRa Institute of Neurological Diseases
state: New South Wales
city: Heidelberg West
country: Australia
facility: Medical & Cognitive Research Unit, Heidelberg Repatriation Hospital - Austin Health
state: Victoria
city: Nedlands
country: Australia
facility: Australian Alzheimer's Research Foundation
state: Western Australia
city: Bath
country: United Kingdom
facility: The Research Institute for the Care of Older People
state: Combe Park
city: Manchester
country: United Kingdom
facility: Manchester Mental Health & Social Care Trust - Dementia Research Office - Park House North Manchester General Hospital
state: Lancashire
city: Isleworth
country: United Kingdom
facility: West London Mental Health Trust
state: London
city: Kings Cross
country: United Kingdom
facility: St Pancras Clinical Research
state: London
city: Belfast
country: United Kingdom
facility: Institute of Clinical Sciences, Queen's University Belfast
state: Northern Ireland
city: Edinburgh
country: United Kingdom
facility: Centre for Clinical Brain Sciences, Centre for Dementia Prevention, The University of Edinburgh
Study officials:
affiliation: Actinogen Medical
name: Bill Ketelbey, MD
role: STUDY_CHAIR
affiliation: Actinogen Medical
name: Alan Boyd, MD, FFPM
role: STUDY_DIRECTOR
References:
citation: Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25.